91 related articles for article (PubMed ID: 22925002)
1. Self-assembling nanoparticles for the release of bisphosphonates in the treatment of human cancers [WO2012042024].
Gou J; Zhang K; Tang X
Expert Opin Ther Pat; 2012 Nov; 22(11):1367-75. PubMed ID: 22925002
[TBL] [Abstract][Full Text] [Related]
2. Self-assembly nanoparticles for the delivery of bisphosphonates into tumors.
Salzano G; Marra M; Porru M; Zappavigna S; Abbruzzese A; La Rotonda MI; Leonetti C; Caraglia M; De Rosa G
Int J Pharm; 2011 Jan; 403(1-2):292-7. PubMed ID: 21055454
[TBL] [Abstract][Full Text] [Related]
3. New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study.
Marra M; Salzano G; Leonetti C; Porru M; Franco R; Zappavigna S; Liguori G; Botti G; Chieffi P; Lamberti M; Vitale G; Abbruzzese A; La Rotonda MI; De Rosa G; Caraglia M
Biotechnol Adv; 2012; 30(1):302-9. PubMed ID: 21741464
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticles for the delivery of zoledronic acid to prostate cancer cells: a comparative analysis through time lapse video-microscopy technique.
Schiraldi C; Zappavigna S; D' Agostino A; Porto S; Gaito O; Lusa S; Lamberti M; De Rosa M; De Rosa G; Caraglia M
Cancer Biol Ther; 2014; 15(11):1524-32. PubMed ID: 25482949
[TBL] [Abstract][Full Text] [Related]
5. Bone substitute materials delivering zoledronic acid: physicochemical characterization, drug load, and release properties.
Sörensen TC; Arnoldi J; Procter P; Robioneck B; Steckel H
J Biomater Appl; 2013 Feb; 27(6):727-38. PubMed ID: 22090432
[TBL] [Abstract][Full Text] [Related]
6. Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells.
Shmeeda H; Amitay Y; Gorin J; Tzemach D; Mak L; Ogorka J; Kumar S; Zhang JA; Gabizon A
J Control Release; 2010 Aug; 146(1):76-83. PubMed ID: 20462513
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
[TBL] [Abstract][Full Text] [Related]
8. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
[TBL] [Abstract][Full Text] [Related]
9. In vivo distribution of zoledronic acid in a bisphosphonate-metal complex-based nanoparticle formulation synthesized by a reverse microemulsion method.
Li X; Naguib YW; Cui Z
Int J Pharm; 2017 Jun; 526(1-2):69-76. PubMed ID: 28455136
[TBL] [Abstract][Full Text] [Related]
10. Could local delivery of bisphosphonates be a new therapeutic choice for hemangiomas?
Yu H; Qin A
Med Hypotheses; 2009 Oct; 73(4):495-7. PubMed ID: 19625131
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid: multiplicity of use across the cancer continuum.
Lipton A
Expert Rev Anticancer Ther; 2011 Jul; 11(7):999-1012. PubMed ID: 21806323
[TBL] [Abstract][Full Text] [Related]
12. Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer.
Montague R; Hart CA; George NJ; Ramani VA; Brown MD; Clarke NW
Eur Urol; 2004 Sep; 46(3):389-401; discussion 401-2. PubMed ID: 15306113
[TBL] [Abstract][Full Text] [Related]
13. Anticancer properties of zoledronic acid.
Green J; Lipton A
Cancer Invest; 2010 Nov; 28(9):944-57. PubMed ID: 20879838
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
[TBL] [Abstract][Full Text] [Related]
15. Low-dose zoledronic acid reduces spinal cord metastasis in pulmonary adenocarcinoma with neuroendocrine differentiation.
Li YY; Chang JW; Hsieh LL; Chen SM; Yeh KY
Anticancer Drugs; 2012 Oct; 23(9):970-8. PubMed ID: 22713592
[TBL] [Abstract][Full Text] [Related]
16. Novel biomaterials for bisphosphonate delivery.
Josse S; Faucheux C; Soueidan A; Grimandi G; Massiot D; Alonso B; Janvier P; Laïb S; Pilet P; Gauthier O; Daculsi G; Guicheux JJ; Bujoli B; Bouler JM
Biomaterials; 2005 May; 26(14):2073-80. PubMed ID: 15576181
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor potential of bisphosphonates.
Green JR
Med Klin (Munich); 2000 Oct; 95 Suppl 2():23-8. PubMed ID: 11089384
[TBL] [Abstract][Full Text] [Related]
18. Impact of zoledronic acid on renal function in patients with cancer: Clinical significance and development of a predictive model.
McDermott RS; Kloth DD; Wang H; Hudes GR; Langer CJ
J Support Oncol; 2006; 4(10):524-9. PubMed ID: 17136870
[TBL] [Abstract][Full Text] [Related]
19. The tumor accumulation and therapeutic efficacy of doxorubicin carried in calcium phosphate-reinforced polymer nanoparticles.
Min KH; Lee HJ; Kim K; Kwon IC; Jeong SY; Lee SC
Biomaterials; 2012 Aug; 33(23):5788-97. PubMed ID: 22591612
[TBL] [Abstract][Full Text] [Related]
20. Gene delivery with bisphosphonate-stabilized calcium phosphate nanoparticles.
Giger EV; Puigmartí-Luis J; Schlatter R; Castagner B; Dittrich PS; Leroux JC
J Control Release; 2011 Feb; 150(1):87-93. PubMed ID: 21111013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
